Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
MD-224 achieves complete and durable tumor regression in vivo in the RS4
Triazolotriazine derivatives as a2a receptor antagonists
220662-95-3 (RJR-2403 oxalate(1:1))
Smiles: CC(=O)O[C@@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5[C@@H](C)[C@H](C)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C)C(O)=O
Bivalirudin TFA 161AK1/MAP4K2 inhibitor 1 MD-224 achieves complete and durableBivalirudin TFA is a synthetic 20 residue peptide which reversibly inhibits thrombin. IC50 Value: Target: thrombin in vitro: Eptifibatide (8 mg mL) added together with a low (70 ng mL) concentration of bivalirudin (a direct thrombin inhibitor) effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0. 2 U mL) . In thrombin generation assay (TGA), bivalirudin had no effect on these parameters up to 10 mol l . Bivalirudin
US$ 174.00
US$ 131.50
US$ 165.50
US$ 168.50
US$ 174.00
US$ 3332.50